Trial Profile
A study to demonstrate the safety and efficacy of lamivudine for the management of hepatitis B virus (HBV) infection reactivation in immunosuppressed oncohematologic patients (OHPs).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 18 Dec 2015 New trial record